Enhancing the satisfaction with prostate cancer treatment decision with the mHealth progam PROSTANA®: A multicenter randomized controlled trial

Not Applicable

• Conditions: C61; Malignant neoplasm of prostate

• Registration Number: DRKS00024555
• Lead Sponsor: Ferring Arzneimittel GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2020-08-31
• Study Start: 2021-03-04
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 244

Inclusion Criteria

Minimum age of 18 years
- Patients in the participating centers
- Initial diagnosis of PCa (ICD-10 code C61)
- Access to internet-enabled devices
- Classified by physician as capable of participating in the study
- Existing participation forms

Exclusion Criteria

- Under 18 years
- Patients who are already in treatment
- Patients for whom the treatment of a comorbidity is absolutely paramount on basis of the treating urologist

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Satisfaction with Decision (SWD-Scale)

Secondary Outcome Measures

Name	Time	Method
- Psychological Burden (HADS-D)<br>- Decisional Conflict (DCS-D)<br>- Shared Decision Making (SDM)